Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Frans L. G. Erdkamp"'
Autor:
Sophie A. Kurk, Petra H. M. Peeters, Bram Dorresteijn, Pim A. deJong, Marion Jourdan, Geert‐Jan M. Creemers, Frans L. G. Erdkamp, Felix E. deJongh, Peter A. M. Kint, Boelo J. Poppema, Sandra A. Radema, Lieke H. J. Simkens, Bea C. Tanis, Manuel L. R. Tjin‐A‐Ton, Ankie Van Der Velden, Cornelis J. A. Punt, Miriam Koopman, Anne M. May
Publikováno v:
Cancer Medicine, Vol 9, Iss 3, Pp 1033-1043 (2020)
Abstract Background Low skeletal muscle index (SMI) in metastatic colorectal cancer (mCRC) patients is associated with poor outcomes. The prognostic impact of SMI changes during consecutive palliative systemic treatments is unknown. Methods This is a
Externí odkaz:
https://doaj.org/article/434f0b15ebe24d0abcf39821804c932c
Autor:
Lenja Witlox, Anouk E. Hiensch, Miranda J. Velthuis, Charlotte N. Steins Bisschop, Maartje Los, Frans L. G. Erdkamp, Haiko J. Bloemendal, Marlies Verhaar, Daan ten Bokkel Huinink, Elsken van der Wall, Petra H. M. Peeters, Anne M. May
Publikováno v:
BMC Medicine, Vol 16, Iss 1, Pp 1-9 (2018)
Abstract Background In the earlier randomized controlled Physical Activity during Cancer Treatment (PACT) study, we found beneficial effects of an 18-week supervised exercise program on fatigue in patients with newly diagnosed breast or colon cancer
Externí odkaz:
https://doaj.org/article/aa4f15db4abc44ea875e738b8c37b5ea
Autor:
Anouk K M, Claessens, Jan J V, Busschbach, Bram L T, Ramaekers, Frans L G, Erdkamp, Jeanette M, Bouma, A Elise, van Leeuwen-Stok, Vivianne C G, Tjan-Heijnen, Monique E M M, Bos
Publikováno v:
Acta Oncologica, 61(5), 619-624. Routledge/Taylor & Francis Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56b5e077dd118501f9df3bdd08fce02a
https://doi.org/10.1080/0284186x.2022.2033832
https://doi.org/10.1080/0284186x.2022.2033832
Autor:
Marissa Meegdes, Khava I. E. Ibragimova, Dorien J. A. Lobbezoo, Ingeborg J. H. Vriens, Loes F. S. Kooreman, Frans L. G. Erdkamp, M. Wouter Dercksen, Birgit E. P. J. Vriens, Kirsten N. A. Aaldering, Manon J. A. E. Pepels, Linda M. H. van de Winkel, Jolien Tol, Joan B. Heijns, Agnes J. van de Wouw, Natascha A. J. B. Peters, Ananda Hochstenbach-Waelen, Marjolein L. Smidt, Sandra M. E. Geurts, Vivianne C. G. Tjan-Heijnen
Publikováno v:
Breast Cancer Research and Treatment, 192(2), 331-342. Springer, Cham
Purpose The hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) are the main parameters in guiding systemic treatment choices in breast cancer, but can change during the disease course. This study aims to evaluate the biopsy rat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a5e909880f3c106d7fac4396b47579
https://doi.org/10.1007/s10549-021-06472-5
https://doi.org/10.1007/s10549-021-06472-5
Autor:
Birgit E.P.J. Vriens, Marcus W. Dercksen, Vivianne C. G. Tjan-Heijnen, Linda van de Winkel, Nathalie J. A. Teeuwen, Sandra M. E. Geurts, Marissa Meegdes, Maaike de Boer, Frans L. G. Erdkamp, Kirsten N. A. Aaldering, Manon J. Pepels
Publikováno v:
International Journal of Cancer. 150:124-131
In August 2017, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy have been reimbursed in the Netherlands for patients with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer (ABC). This study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07254451752c581f4a03cc52af7d164b
https://doi.org/10.1002/ijc.33785
https://doi.org/10.1002/ijc.33785
Autor:
Mathijs P. Hendriks, J M van Dodewaard-de Jong, J W T Dekker, J.A.G. van der Heijden, Bastiaan R. Klarenbeek, A J G Maaskant-Braat, D J A Sonneveld, T van Voorthuizen, Hein B.A.C. Stockmann, L B J Valkenburg-van Iersel, I.H.J.T. de Hingh, F W H Kloppenberg, G R Vink, Seyed M. Qaderi, F H Beverdam, K Talsma, A H W Schiphorst, J F J Vogelaar, Frans L. G. Erdkamp, H W M U van Grevenstein, W J Vles, Marco B. Polee, Jan B.M.J. Jansen, H H Helgason, P P L O Coene, Geerard L. Beets, E J Th Belt, A U G van Lent, Jan N. M. IJzermans, D D E Zimmerman, M L R Tjin-A-Ton, A J ten Tije, M Berbée, Leonie J. M. Mekenkamp, M P S Sie, Annebeth W. Haringhuizen, Koen C.M.J. Peeters, Maartje Los, A M T van der Velden, N A J B Peters, J W B de Groot, Martijn R. Meijerink, A Schouten van der Velden, A I de Vos, J.H.W. de Wilt, Lieke H.J. Simkens, E G G Verdaasdonk, José A. E. Custers, Peter Nieboer, Rob H.A. Verhoeven, M Vermaas, F Terheggen, P Quarles van Ufford-Mannesse, R Blankenburgh, R Hoekstra, R W M Schrauwen, Dirkje W. Sommeijer, R C Rietbroek, H van Cruijsen, L E A Spierings
Publikováno v:
British journal of surgery, 108(8), 991-997. John Wiley and Sons Ltd
British Journal of Surgery, 108(8), 991-997. Wiley
PLCRC group 2021, ' Transanal total mesorectal excision and low anterior resection syndrome ', British Journal of Surgery, vol. 108, no. 8, pp. 991-997 . https://doi.org/10.1093/bjs/znab056
British Journal of Surgery, 108, 8, pp. 991-997
British Journal of Surgery, 108, 991-997
British Journal of Surgery, 108(8), 991-997. John Wiley and Sons Ltd
British Journal of Surgery, 108(8), 991-997. Wiley
PLCRC group 2021, ' Transanal total mesorectal excision and low anterior resection syndrome ', British Journal of Surgery, vol. 108, no. 8, pp. 991-997 . https://doi.org/10.1093/bjs/znab056
British Journal of Surgery, 108, 8, pp. 991-997
British Journal of Surgery, 108, 991-997
British Journal of Surgery, 108(8), 991-997. John Wiley and Sons Ltd
Background Bowel dysfunction after rectal cancer surgery is common, with some experiencing low anterior resection syndrome (LARS) is common after rectal cancer surgery. This study examined if transanal total mesorectal excision (TaTME) has a similar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c1fcf9a92def7659b2c98d0089aa720
http://www.scopus.com/inward/record.url?scp=85116172373&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85116172373&partnerID=8YFLogxK
Autor:
Sandra M. E. Geurts, Maaike de Boer, M. Wouter Dercksen, Dominique. J. P. Tilli, Vivianne C. G. Tjan-Heijnen, Manon J. Pepels, Khava I.E. Ibragimova, Frans L. G. Erdkamp, Marien O den Boer, Birgit Epj Vriens
Publikováno v:
Cancer Research. 80:P2-08
Background The aim of this study was to determine the subtype conversion rate and the initial systemic treatment choices by subtype for patients diagnosed with advanced breast cancer since 2007 who were included in the SONABRE Registry. Patients and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8382c1fdd3dc0a31895fb397d65fd8db
https://doi.org/10.1158/1538-7445.sabcs19-p2-08-06
https://doi.org/10.1158/1538-7445.sabcs19-p2-08-06
Autor:
Sandra M. E. Geurts, Marien O den Boer, Khava I.E. Ibragimova, Maaike de Boer, Frans L. G. Erdkamp, Birgit Epj Vriens, Vivianne C. G. Tjan-Heijnen, M. Wouter Dercksen, Manon J. Pepels, Nathalie J. A. Teeuwen
Publikováno v:
Cancer Research. 80:P1-19
Background Previously, we reported that patients with HR+/HER2+ advanced breast cancer diagnosed in 2007-2009 had a better overall survival (OS) than patients with HR-/HER2+ advanced breast cancer (SONABRE Registry, Lobbezoo et al. BCRT 2013). This d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d47a1234dd53235804586280b9f76a84
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-34
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-34
Autor:
Jeany M. Rademaker-Lakhai, Frans L. G. Erdkamp, Monique E. M. M. Bos, Anouk K. M. Claessens, Vivianne C. G. Tjan-Heijnen, Jeanette M. Bouma, Reinier Timman, Jan J. Busschbach
Publikováno v:
Breast Cancer Research and Treatment, 179(3), 677-685. Springer, Cham
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 179, 677-685. Springer New York
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 179, 677-685. Springer New York
Background The Stop&Go study randomized patients with advanced breast cancer to intermittent (two times four) or continuous (eight subsequent cycles) first- and second-line chemotherapy. Methods QoL was measured with RAND-36 questionnaires every 12 w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96344c15a8e4dd858487114a3426694b
https://doi.org/10.1007/s10549-019-05495-3
https://doi.org/10.1007/s10549-019-05495-3
Autor:
Marissa, Meegdes, Sandra M E, Geurts, Frans L G, Erdkamp, Marcus Wouter, Dercksen, Birgit E P J, Vriens, Kirsten N A, Aaldering, Manon J A E, Pepels, Linda M H, van de Winkel, Nathalie J A, Teeuwen, Maaike, de Boer, Vivianne C G, Tjan-Heijnen
Publikováno v:
International journal of cancer. 150(1)
In August 2017, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy have been reimbursed in the Netherlands for patients with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer (ABC). This study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f901f174bde16a07955291e70ce75b93
https://pubmed.ncbi.nlm.nih.gov/34460112
https://pubmed.ncbi.nlm.nih.gov/34460112